Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults

A Phase IV, Uncontrolled, Open-label, Single-center Study in Adolescents and Adults: Evaluation of Immunogenicity and Safety of the First Booster Immunization With Novartis' TBE Vaccine for Adults in Participants of Study V48P7 and Long-term Evaluation of Immunogenicity up to 5 Years After First Booster Immunization

evaluate safety and immunogenicity of first TBE booster and long-term immunogenicity up to 5 years after first TBE booster

Inclusion Criteria:

• healthy subjects who have completed study V48P7

Exclusion Criteria:

• acute illness at day of immunization
• general decrease in resistance
• progressive neurological disorders
• history of febrile or afebrile convulsions
• major congenital defects
• serious chronic illness
• hypersensitivity to study vaccine
• treatment with immunosuppressants or systemic corticosteroids, immunoglobulins, whole blood or plasma derivates